302 related articles for article (PubMed ID: 25487791)
21. Treatment outcomes of secondary bacteraemia in patients treated with ceftaroline fosamil: pooled results from six phase III clinical trials.
Dryden M; Kantecki M; Yan JL; Stone GG; Leister-Tebbe H; Wilcox M
J Glob Antimicrob Resist; 2022 Mar; 28():108-114. PubMed ID: 34922058
[TBL] [Abstract][Full Text] [Related]
22. Usefulness of betalactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin-clavulanate and ceftriaxone.
Rosón B; Carratalà J; Tubau F; Dorca J; Liñares J; Pallares R; Manresa F; Gudiol F
Microb Drug Resist; 2001; 7(1):85-96. PubMed ID: 11310807
[TBL] [Abstract][Full Text] [Related]
23. Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: a US-based study.
Frei CR; Jaso TC; Mortensen EM; Restrepo MI; Raut MK; Oramasionwu CU; Ruiz AD; Makos BR; Ruiz JL; Attridge RT; Mody SH; Fisher A; Schein JR
Curr Med Res Opin; 2009 Apr; 25(4):859-68. PubMed ID: 19231913
[TBL] [Abstract][Full Text] [Related]
24. Relationship between time to clinical response and outcomes among Pneumonia Outcomes Research Team (PORT) risk class III and IV hospitalized patients with community-acquired pneumonia who received ceftriaxone and azithromycin.
Zasowski E; Butterfield JM; McNutt LA; Cohen J; Cosler L; Pai MP; Gottwald J; Chen WZ; Lodise TP
Antimicrob Agents Chemother; 2014 Jul; 58(7):3804-13. PubMed ID: 24752270
[TBL] [Abstract][Full Text] [Related]
25. Ceftaroline fosamil for community-acquired pneumonia.
Pawluk SA; Wilby KJ
Lancet Infect Dis; 2015 Sep; 15(9):999. PubMed ID: 26333321
[No Abstract] [Full Text] [Related]
26. Summary of ceftaroline fosamil clinical trial studies and clinical safety.
File TM; Wilcox MH; Stein GE
Clin Infect Dis; 2012 Sep; 55 Suppl 3():S173-80. PubMed ID: 22903949
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia.
Dresser LD; Niederman MS; Paladino JA
Chest; 2001 May; 119(5):1439-48. PubMed ID: 11348951
[TBL] [Abstract][Full Text] [Related]
28. Ceftaroline fosamil for community-acquired pneumonia--Authors' reply.
Zhong NS; Sun T; Wilson D; Melnick D
Lancet Infect Dis; 2015 Sep; 15(9):999-1000. PubMed ID: 26333322
[No Abstract] [Full Text] [Related]
29. Efficacy and effectiveness of Ceftaroline Fosamil in patients with pneumonia: a systematic review and meta-analysis.
Sotgiu G; Aliberti S; Gramegna A; Mantero M; Di Pasquale M; Trogu F; Saderi L; Blasi F
Respir Res; 2018 Oct; 19(1):205. PubMed ID: 30352588
[TBL] [Abstract][Full Text] [Related]
30. Ceftaroline fosamil as first-line versus second-line treatment for acute bacterial skin and skin structure infections (ABSSSI) or community-acquired bacterial pneumonia (CABP).
Guervil DJ; Kaye KS; Hassoun A; Cole P; Huang XY; Friedland HD
J Chemother; 2016 Jun; 28(3):180-6. PubMed ID: 25817579
[TBL] [Abstract][Full Text] [Related]
31. Ceftaroline Fosamil for the Treatment of Community-Acquired Pneumonia: from FOCUS to CAPTURE.
Carreno JJ; Lodise TP
Infect Dis Ther; 2014 Dec; 3(2):123-32. PubMed ID: 25193094
[TBL] [Abstract][Full Text] [Related]
32. Review of ceftaroline fosamil microbiology: integrated FOCUS studies.
Critchley IA; Eckburg PB; Jandourek A; Biek D; Friedland HD; Thye DA
J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii45-51. PubMed ID: 21482569
[TBL] [Abstract][Full Text] [Related]
33. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia.
Pertel PE; Bernardo P; Fogarty C; Matthews P; Northland R; Benvenuto M; Thorne GM; Luperchio SA; Arbeit RD; Alder J
Clin Infect Dis; 2008 Apr; 46(8):1142-51. PubMed ID: 18444848
[TBL] [Abstract][Full Text] [Related]
34. Ceftaroline fosamil for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection.
Casapao AM; Steed ME; Levine DP; Rybak MJ
Expert Opin Pharmacother; 2012 Jun; 13(8):1177-86. PubMed ID: 22594846
[TBL] [Abstract][Full Text] [Related]
35. Clinical cure with ceftriaxone versus ceftaroline or ceftobiprole in the treatment of staphylococcal pneumonia: a systematic review and meta-analysis.
Eljaaly K; Wali H; Basilim A; Alharbi A; Asfour HZ
Int J Antimicrob Agents; 2019 Aug; 54(2):149-153. PubMed ID: 31173864
[TBL] [Abstract][Full Text] [Related]
36. Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia in elderly patients.
Udeani G; Evans J; Cole P; Friedland HD
Hosp Pract (1995); 2014 Aug; 42(3):109-15. PubMed ID: 25255412
[TBL] [Abstract][Full Text] [Related]
37. [Zinforo™ (ceftaroline fosamil)--A new beta-lactam-cephalosporin with MRSA activity].
Welte T
Dtsch Med Wochenschr; 2014 Nov; 139 Suppl 3():S89-90. PubMed ID: 25429539
[No Abstract] [Full Text] [Related]
38. Contemporary use of ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia: CAPTURE study experience.
Ramani A; Udeani G; Evans J; Jandourek A; Cole P; Smith A; David Friedland H
J Chemother; 2014 Aug; 26(4):229-34. PubMed ID: 24650326
[TBL] [Abstract][Full Text] [Related]
39. [Ceftaroline: new possibilities of short-term courses of antibacterial therapy in hospitalized patients with extramural pneumonia].
Sinipal'nikov AI
Klin Med (Mosk); 2014; 92(1):21-7. PubMed ID: 25265655
[TBL] [Abstract][Full Text] [Related]
40. Ceftaroline fosamil for treating skin and skin structure infections or community-acquired pneumonia in patients with renal insufficiency.
Maggiore C; Pasquale T; Cole P; Friedland HD
Expert Rev Clin Pharmacol; 2015 Jan; 8(1):141-53. PubMed ID: 25467425
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
